Prosecution Insights
Last updated: November 20, 2026
Application No. 18/559,810

STEM CELL INDUCTION INTO PRECHONDROCYTES AND DIFFERENTIATION INTO CHONDROCYTES BY CIPROFLOXACIN

Non-Final OA §102
Filed
Nov 09, 2023
Priority
May 12, 2021 — RE 10-2021-0061406 +1 more
Examiner
DHAR, MATASHA
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Smart Cell Lab Co. Ltd.
OA Round
1 (Non-Final)
45%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 45% of resolved cases
45%
Career Allowance Rate
42 granted / 94 resolved
-15.3% vs TC avg
Strong +46% interview lift
Without
With
+46.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
37 currently pending
Career history
148
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
34.8%
-5.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 94 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 1-3, 45-48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected group, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 3/9/2026. Applicant’s election without traverse of Group II, claims 4 and 5 in the reply filed on 3/9/2026 is acknowledged. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Drawings The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they do not include the following reference sign(s) mentioned in the description: Figures 4A and 4B. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Specification The disclosure is objected to because of the following informalities: 1. The description for Figures 3A and 3B on page 21 do not match the figures actually presented in the drawings as figures 3A and 3B. 2. The description for Figures 4A and 4B on page 21 do not match the figures actually presented in the drawings as figure 4. 3. The result for Example 2 on page 24, para 3 refers to Figure 3A as showing chondrocyte staining but actual Figure 3A shows viability results. 4. The result for Example 3 on page 25, para 1 refers to Figure 3B as showing chondrocyte staining but actual Figure 3B shows size of 3D cultured cells. 5. The result for Example 4 on page 25, para 3 refers to Figures 4A and 4B as showing chondroprogenitor characteristics and results from karyotype analysis but actual Figure 4 is the cytology report of stem cells collected from the patient. Appropriate corrections are required. Claim Interpretation Claim 4 is a composition comprising ciprofloxacin. The intended use recited in the preamble for the claimed composition is “for inducing stem cells into chondrocytes”. According to MPEP 2111.02, “If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction”. The intended use recited in claim 4 does not appear to impart any structure to the claimed product. Therefore, claim 4 is a composition comprising ciprofloxacin. Claim 5 recites a more specific intended use for the composition of claim 4, reciting “wherein the stem cells are mesenchymal stem cells”. Based on the guidance from MPEP 2111.02 presented above regarding intended use, since the intended use recited in claim 5 does not appear to impart any structure to the claimed product. Therefore, claim 5 is also composition comprising ciprofloxacin. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 4 and 5 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kiratipaiboon et al (Stem Cells Int. 2016;2016:5831276. Epub 2015 Nov 16). Kiratipaiboon discloses a composition comprising ciprofloxacin (2. Material and Methods: Cells and Reagents; Figures 1-5). Therefore, Kiratipaiboon anticipates the claimed composition. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATASHA DHAR whose telephone number is (571)272-1680. The examiner can normally be reached M-F 8am-4pm (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras Jr. can be reached at (571)272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATASHA DHAR/Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Nov 09, 2023
Application Filed
Apr 28, 2026
Non-Final Rejection mailed — §102
Sep 25, 2026
Response Filed
Sep 25, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12742156
METHODS AND SYSTEMS FOR TRANSPORTATION AND CULTURE OF BUOYANT TISSUE
5y 6m to grant Granted Sep 22, 2026
Patent 12741059
METHOD FOR CONTROLLING YOUNG'S MODULUS OF THREE-DIMENSIONAL TISSUE BODY, METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY, AND THREE-DIMENSIONAL TISSUE BODY
4y 0m to grant Granted Sep 22, 2026
Patent 12642257
NON-HUMAN VERTEBRATE COMPRISING HUMAN LIVER CELLS TRANSPLANTED THEREIN AND METHOD FOR PRODUCING THE SAME
5y 7m to grant Granted Jun 02, 2026
Patent 12628802
GENETICALLY MODIFIED RAT HAVING PKHD1L1 GENE WITH POINT MUTATION AND METHODS FOR ITS CONSTRUCTION, DETECTION AND USE
1y 6m to grant Granted May 19, 2026
Patent 12611436
AAV TRANSFER CASSETTE
5y 6m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
45%
Grant Probability
91%
With Interview (+46.2%)
3y 9m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 94 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month